A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

Preclinical studies indicate autophagy inhibition with hydroxychloroquine (HCQ) can augment the efficacy of DNA-damaging therapy. The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma (GB). A 3 + 3 phase I trial design followed by a noncomparative phase II study was conducted in GB patients after initial resection. Patients received HCQ (200 to 800 mg oral daily) with RT and concurrent and adjuvant TMZ. Quantitative electron microscopy and immunoblotting were used to assess changes in autophagic vacuoles (AVs) in peripheral blood mononuclear cells (PBMC). Population pharmacokinetic (PK) modeling enabled PK-pharmacodynamic correlations. Sixteen phase I subjects were evaluable for dose-limiting toxicities. At 800 mg HCQ/d, 3/3 subjects experienced Grade 3 and 4 neutropenia and thrombocytopenia, 1 with sepsis. HCQ 600 mg/d was found to be the MTD in this combination. The phase II cohort (n = 76) had a median survival of 15.6 mos with survival rates at 12, 18, and 24 mo of 70%, 36%, and 25%. PK analysis indicated dose-proportional exposure for HCQ. Significant therapy-associated increases in AV and LC3-II were observed in PBMC and correlated with higher HCQ exposure. These data establish that autophagy inhibition is achievable with HCQ, but dose-limiting toxicity prevented escalation to higher doses of HCQ. At HCQ 600 mg/d, autophagy inhibition was not consistently achieved in patients treated with this regimen, and no significant improvement in overall survival was observed. Therefore, a definitive test of the role of autophagy inhibition in the adjuvant setting for glioma patients awaits the development of lower-toxicity compounds that can achieve more consistent inhibition of autophagy than HCQ.

[1]  Q. Zhong.  Faculty Opinions recommendation of Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. , 2015 .

[2]  J. Bradner,et al.  Combined autophagy and proteasome inhibition , 2014, Autophagy.

[3]  T. Curiel,et al.  Combined autophagy and HDAC inhibition , 2014, Autophagy.

[4]  A. Troxel,et al.  Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma , 2014, Autophagy.

[5]  R. Amaravadi,et al.  Autophagy: a targetable linchpin of cancer cell metabolism , 2013, Trends in Endocrinology & Metabolism.

[6]  D. Rubinsztein,et al.  Autophagy modulation as a potential therapeutic target for diverse diseases , 2012, Nature Reviews Drug Discovery.

[7]  Michael S. Lee.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy , 2011 .

[8]  S. Katz,et al.  Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action , 2011, Current opinion in rheumatology.

[9]  William A Weiss,et al.  Principles and Current Strategies for Targeting Autophagy for Cancer Treatment , 2011, Clinical Cancer Research.

[10]  L. Moretti,et al.  Endoplasmic Reticulum Stress Mediates Radiation-Induced Autophagy via PERK-eIF2α in Caspase-3/7 Deficient Cells , 2010, Oncogene.

[11]  Jae-Won Park,et al.  Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax , 2009, Antimicrobial Agents and Chemotherapy.

[12]  N. Buckley,et al.  Survival after Massive Hydroxychloroquine Overdose , 2009, Anaesthesia and intensive care.

[13]  M. Berger,et al.  DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells , 2007, Cell Death and Differentiation.

[14]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.

[15]  Kevin Bray,et al.  Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. , 2006, Cancer cell.

[16]  J. Sotelo,et al.  Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme , 2006, Annals of Internal Medicine.

[17]  Hoyun Lee,et al.  Chloroquine-Mediated Radiosensitization is due to the Destabilization of the Lysosomal Membrane and Subsequent Induction of Cell Death by Necrosis , 2005, Radiation research.

[18]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Smith,et al.  Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. , 2005, The Journal of emergency medicine.

[20]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  Chi Li,et al.  Growth Factor Regulation of Autophagy and Cell Survival in the Absence of Apoptosis , 2005, Cell.

[22]  F. Romanelli,et al.  Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. , 2004, Current pharmaceutical design.

[23]  I. Germano,et al.  Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells , 2004, Cell Death and Differentiation.

[24]  S. Tett,et al.  Population Pharmacokinetics of Hydroxychloroquine in Patients With Rheumatoid Arthritis , 2003, Therapeutic drug monitoring.

[25]  R. Vij,et al.  Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  M. Marmor,et al.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.

[27]  D. Gerber,et al.  The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. , 2007, Neuro-oncology.

[28]  B. K. Park,et al.  4-Aminoquinolines--past, present, and future: a chemical perspective. , 1998, Pharmacology & therapeutics.